

A close-up photograph of two hands held up, palms facing each other. The skin is light brown and has several irregular white patches, characteristic of vitiligo. The background is solid black. The text 'GLOBAL VITILIGO FOUNDATION' is overlaid at the top, and '2023 Annual Scientific Symposium' is overlaid at the bottom.

**GLOBAL
VITILIGO
FOUNDATION**

**2023
Annual
Scientific
Symposium**

THANK YOU TO OUR GENEROUS SPONSORS

Gold
\$50K+



Silver
\$25K+



Bronze
\$10K+



Bronze
\$15K+



Breakfast and Poster Viewing	7:00 - 8:00 AM
Welcome Message - Amit G. Pandya, MD	8:00 - 8:20 AM
Abstract #1 - Katie Bush, PhD <i>Cellular Characterization and Evidence of Melanocyte Transfer of Autologous Skin Cell Suspension Prepared using RECELL® Autologous Cell Harvesting Device</i>	8:20 - 8:32 AM
Abstract #2 - Nicole Mastacouris, MS <i>Incidence and Prevalence of Vitiligo in the United States</i>	8:32 - 8:44 AM
Abstract #3 - David Rosmarin, MD <i>Patient Burden of Nonsegmental Vitiligo: Perspectives from US Patients</i>	8:44 - 8:56 AM
Vitiligo Support Committee Update - Richard Huggins, MD	8:56 - 9:06 AM
Abstract #4 - Angela Calaguas, BS <i>Skin Infections as a Marker of Vitiligo Activity: A Prospective and Retrospective Study</i>	9:06 - 9:18 AM
Invited Speaker - Iltefat Hamzavi, MD <i>The Intersection of Society, Science and Therapeutics: How We All Built Our Vitiligo Community</i>	9:18 - 9:50 AM
Abstract #5 - Abigail Sloan, PhD <i>An Analysis of Inter-Rater and Intra-Rater F-VASI Assessments in Adults With Active Non-segmental Vitiligo</i>	9:50 - 10:02 AM
Coffee Break & Poster Viewing	10:02 - 10:30 AM
Abstract #6 - Kristin Tissera, BS <i>Vitiligo and Identity</i>	10:30 - 10:42 AM
Invited Speaker - Thierry Passeron, MD, PhD <i>Validation of an Objective and Accurate Measurement of Facial Depigmentation for Vitiligo Using Standardized UV Pictures and a Dedicated Algorithm of Analysis</i>	10:42 - 11:14 AM
VOICE Update - Khaled Ezzedine, MD, PhD	11:14 - 11:24 AM
Difficult Cases: Panel Case Studies - Pearl Grimes, MD; Khaled Ezzedine, MD, PhD; Davinder Parsad, MD; John E. Harris, MD Marwa Abdallah, MD	11:24 AM - 12:08 PM
Persons With Vitiligo (PWV) Panel - Tonja Johnson, Sharon King, Alicia Roufs,	12:08 - 12:25 PM
Meeting Wrap-Up	12:25 - 12:30 PM

A MESSAGE FROM THE SCIENTIFIC MEETINGS CO-CHAIRS



Dear GVF Colleagues, Friends, and Supporters,

Welcome to the 2023 GVF Annual Scientific Symposium! We are delighted to bring together vitiligo experts and researchers from all over the world, along with patients and our industry partners.

Our program will offer you informative and insightful content from Invited Speakers Iltefat Hamzavi, MD and Thierry Passeron, MD, PhD, several oral abstracts, vitiligo updates and an enlightening panel discussion reviewing difficult cases with leading vitiligo experts. We will also have a panel with Persons with Vitiligo, which will be very meaningful.

We hope you enjoy this year's Symposium and take home lots of ideas, insights, and inspiration!

We invite you to ask questions of our presenters and join in the dialogue.

Thank you for joining us for today's program.

SCIENTIFIC MEETINGS COMMITTEE

Jung Min Bae, MD, PhD
Marcel Bekkenk, MD, PhD
Seemal R. Desai, MD, FAAD
Viktoria Eleftheriadou, MD
Samia Esmat Mohamed, MD
Khaled Ezzedine MD, PhD
Iltefat Hamzavi, MD
John E. Harris, MD, PhD
Amit G. Pandya, MD
Davinder Parsad, MD
Mauro Picardo, MD
Nanja van Geel MD, PhD
Albert Wolkerstorfer, MD, PhD



Samia Esmat, MD
*Co-Chair Scientific Meetings
Committee*



Davinder Parsad, MD
*Co-Chair Scientific Meetings
Committee*

A MESSAGE FROM THE GVF PRESIDENT

Dear Global Vitiligo Foundation Colleagues and Friends,

Welcome to the 2023 Global Vitiligo Foundation Annual Scientific Symposium!

We are delighted to have you with us for today's program, which features several esteemed vitiligo experts, emerging researchers and valued members of the vitiligo community.

Our GVF Scientific Committee, co-chaired by Dr. Samia Esmat and Dr. Davinder Parsad, has developed an excellent and enriching scientific program spanning many important topics in vitiligo, including Invited Speakers, moderated panel discussions, oral abstract presentations, vitiligo updates and scientific poster viewing.

We gratefully acknowledge our Annual Symposium 2023 Sponsors, whose support has helped make today's program possible: Avita Medical, AbbVie, Strata Skin Sciences, and My Vitiligo Team.

We hope that you gain new insights and benefit from today's symposium.

Thank you for joining us and for being a part of our Global Vitiligo Foundation Community!

Warm regards,

Amit G. Pandya, MD, FAAD
GVF President



THE GLOBAL VITILIGO FOUNDATION

OFFICERS

PRESIDENT

Amit G. Pandya, MD
Palo Alto Foundation Medical Group & The University of Texas Southwestern Medical Center

TREASURER

Richard H. Huggins, MD
Henry Ford Health System

IMMEDIATE PAST PRESIDENT

Iltefat Hamzavi, MD, FAAD
Hamzavi Dermatology & Henry Ford Hospital

VICE PRESIDENT VITILIGO SUPPORT

Kim Boyd
Comerica Bank

BOARD OF DIRECTORS

Seemal R. Desai, MD, FAAD
Innovative Dermatology & The University of Texas Southwestern Medical Center

Nada Elbuluk, MD, MSc, FAAD
Keck Hospital of University of Southern California

Samia Esmat, MD
*Faculty of Medicine
Cairo University, Egypt*

Pearl Grimes, MD, FAAD
Vitiligo and Pigmentation Institute of Southern California

John E. Harris, MD, PhD, FAAD
University of Massachusetts Medical School

Efrem Kamen
Pura Vida Investments & Columbia University

Harvey Lui, MD
University of British Columbia

Davinder Parsad, MD, FRCP
Postgraduate Institute of Medical Education & Research, Chandigarh, India

Stephen Taylor
V-Strong Support Group

STAFF

Technical Registration Experts, Inc.

EXECUTIVE DIRECTOR

Sheila Lyons

DIRECTOR OF OPERATIONS

Patrick M. Dockins, MS, CAE

INTEGRATED COMMUNICATIONS MANAGER

Nancy Balik FitzGerald, BS

BOOKKEEPER

Zach Miller

DATABASE & TECHNICAL SUPPORT

Jeffrey Miller

FINANCE, ACCOUNTING

Monica McCue, MBA
Desmond & Ahern, Ltd.

SPEAKERS



AMIT G. PANDYA, MD

*Palo Alto Foundation Medical Group
Department of Dermatology - University of Texas Southwestern
Medical Center*

GVF Roles

President; Medical Advisory Board Chair

Welcome Address

Moderator: Difficult Cases Panel



ILTEFAT HAMZAVI, MD

*Staff Physician - Henry Ford Hospital
Physician - Hamzavi Dermatology*

GVF Roles

*Immediate Past-President; Nominations Committee Chair,
Development Committee*

Title of Presentation:

*The Intersection of Society, Science and Therapeutics:
How We All Built Our Vitiligo Community*



THIERRY PASSERON, MD, PHD

*Professor and Chair, Department of Dermatology, Université Côte
d'Azur in Nice, France*

Title of Presentation:

*Validation of an Objective and Accurate
Measurement of Facial Depigmentation for Vitiligo
Using Standardized UV Pictures and a Dedicated
Algorithm of Analysis*

SPEAKERS



RICHARD HUGGINS, MD

Dermatologist, Vitiligo Research and Treatment Center at Henry Ford Hospital

GVF Roles

Treasurer; Chair, Finance Committee; Nominations Committee; Vitiligo Support Committee; Chair, Global Vitiligo Foundation-Community

Vitiligo Support Committee and Vitiligo Community Update

Moderator: Persons With Vitiligo (PWV) Panel



KHALED EZZEDINE, MD, PHD

*Department of Dermatology, Hôpital Henri Mondor
Researcher, INSERM U1153/INRA U1125 of the Paris 13 University.*

VOICE Update

Vitiligo Outcome Instruments and Consensus for Evidence

PLEASE SHARE WITH YOUR VITILIGO PATIENTS OR COMMUNITY



World Vitiligo Day-USA

June 23 - 25, 2023

Atlanta, GA

2023.wvdusa.org

ORAL ABSTRACT PRESENTERS



Katie Bush, PhD

Senior VP, Scientific & Medical Affairs, AVITA Medical

Cellular Characterization and Evidence of Melanocyte Transfer of Autologous Skin Cell Suspension Prepared using RECELL® Autologous Cell Harvesting Device

Katie has a doctorate in Biomedical Engineering & Medical Physics and has 22 years of experience in scientific research in the field of regenerative skin and soft tissue technologies. She has 13 years of industry experience working with medical devices including wound dressings, cellular and tissue derived products, dermal regeneration templates, and autologous skin harvesting systems. Katie has authored various publications and book chapters focused on tissue engineering approaches to skin regeneration.



Nicole Mastacouris, MS

*Research Fellow at Northwell Health Department of Dermatology.
MD student at Loyola University Chicago Stritch School of Medicine.*

Prevalence and Incidence of Vitiligo in the United States



David Rosmarin, MD

*Chair of the Department of Dermatology
Indiana University School of Medicine*

Patient Burden of Nonsegmental Vitiligo: Perspectives from US Patients

David Rosmarin went to Harvard College where he received his bachelors degree in chemistry and physics and masters degree in chemistry. After graduating with honors from NYU School of Medicine, he completed his internship at Columbia Presbyterian Hospital and dermatology residency at Boston University-Tufts University Combined Dermatology Residency Training Program. After a post-doc at Brigham and Women's Hospital, Dr. Rosmarin

returned to join Tufts Medical Center faculty where he was Director of the Clinical Trials Unit and Vice-Chair for Research and Education. Dr Rosmarin is currently Chair of the Department of Dermatology at Indiana University School of Medicine, and has responsibility for the department's clinical, education and research programs. Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases of the skin and is dedicated to improving treatments of patients suffering from vitiligo.

ORAL ABSTRACT PRESENTERS



Angela Calaguas, BS

Junior Specialist, University of California, Davis - Dermatology

Skin Infections as a Marker of Vitiligo Activity: A Prospective and Retrospective Study

After graduating from UC Santa Barbara with a B.S. in Biopsychology, Angela Calaguas has worked as a junior specialist for Dr. Victor Huang at the UC Davis Dermatology for a little over two years. During her time, she has worked closely with him on research projects as well as clinical trials that focus on expanding our understanding on the assessment and treatment of vitiligo. Her main research project has been creating a vitiligo patient registry database that looks at a patient's medical history, including treatment history and clinical outcomes, in an effort to better understand how these factors affect vitiligo activity.



Abigail Sloan, PhD

Associate Director of Biostatistics, Pfizer

An Analysis of Inter-Rater and Intra-Rater F-VASI Assessments in Adults With Active Non-segmental Vitiligo

Abigail Sloan is a biostatistician at Pfizer. She is currently an Associate Director of Biostatistics for Early Clinical Development in Cambridge, MA, and she supports development projects in indications related to inflammation and immunology. She recently was the trial statistician for Pfizer's Phase IIb trial for vitiligo.



Kristin Tissera, BS

Medical Student, Duke University School of Medicine

Vitiligo and identity

Kristin Tissera is a second year medical student at Duke University School of Medicine. She graduated from Tufts University, summa cum laude, with majors in Biology and Anthropology in 2020. She wrote her senior thesis, awarded highest honors, on vitiligo and its impacts on identity through the Tufts Anthropology Department. After this time, she spent a year in Singapore as a Fulbright Research Student working on vitiligo and Melasma research at the Skin Research Institute of Singapore.

DIFFICULT CASES PANEL



Pearl Grimes, MD
*The Vitiligo & Pigmentation
Institute of Southern California*



Khaled Ezedine, MD, PhD
*Hôpital Henri Mondor
INSERM U1153/INRA U1125*



John E. Harris, MD, PhD
UMass Chan Medical School



Marwa Abdallah, MD
Ain Shams University (ASU)



Davinder Parsad, MD
*Postgraduate Institute of
Medical Education & Research,
Chandigarh, India*



Amit G. Pandya, MD
*Palo Alto Foundation Medical Group,
Department of Dermatology - University of
Texas Southwestern Medical Center*

POSTERS

224 Sarah Gonzalez, BS

University of Southern California Keck School of Medicine, Department of Dermatology

| Skin Cancer Risk and Sun Protective Practices in Individuals with Vitiligo: A Prospective International Cross-Sectional Survey

Misperceptions remain about the risk of skin cancer from vitiligo and vitiligo associated therapies. Additionally, there remains variation in sun protection behavior, particularly with the need to reapply sunscreen for it to remain effective. Dermatologists can utilize the internet and social media along with partnering with vitiligo support groups to change these misperceptions and fill the educational gaps which currently exist regarding these topics.

225 Botir Saatov, MD

Saatov Vitiligo Clinic

| The Role of the Tyr Tyrosinase Gene Polymorphism in the Mechanism of Vitiligo Development in the Population of Uzbekistan

In the pathogenesis of vitiligo, a special place is occupied by tyrosinase, which is an enzyme of melanocytes. Tyrosinase catalyzes the conversion of the amino acid tyrosine to melanin in specialized pigment cells — melanocytes. The human tyrosinase enzyme is obtained in pure form and consists of 529 amino acid residues with a molecular weight equal to 62.6 daltons. Tyrosinase is encoded by the TYR gene, the cytogenetic localization of which on chromosome is 11.314.3.

In recent years, due to wide-genome-related research, some success has been achieved in uncovering risk-prone vitiligo locus / genes. Most of these loci / genes are associated with the immune system, i.e. with the development of autoimmune diseases. Among them, only one gene, TYR, has an irrelevant relationship with a predisposition to the risk of developing vitiligo.

In the literature, data on the polymorphism of the TYR gene and its connection with the risk of developing vitiligo is extremely small. There are only a few studies on this problem, however, their results are contradictory. Therefore, further research is needed on the association of TYR gene polymorphism with the risk of developing vitiligo.

The purpose of this work is to study the rs 1393350 polymorphism of the TYR gene and the association between this polymorphism and the predisposition to the development of vitiligo.

234 Prachi Khanna, BSA

Dell Medical School at The University of Texas at Austin

| Analysis of Online Resource Utilization Among Individuals with Vitiligo

Dermatology-related information on the internet has been studied extensively, both in general and in the context of specific dermatologic conditions. With regard to vitiligo, studies have analyzed the accuracy of content on websites, such as YouTube and Twitter, and trends in internet use but the views of individuals with vitiligo about online resources and their utility is unknown.

235 Michelle Bach, BS

Dell Medical School at The University of Texas at Austin

| Patient Outcomes of a Novel Melanocyte-Keratinocyte Transplantation Procedure Workflow

This novel MKTP workflow (Figure 1), centered on a collaboration between a biotechnology laboratory and an academic dermatology practice, resulted in 73% (8/11) of MKTP recipients achieving >40% repigmentation from baseline after 1 MKTP session, which was completed by 9/11 patients, or 2 MKTP sessions, which was completed by 2/11 patients. The results of this study were limited by sample size, number of patients lost to follow-up, and the percentage of patients with unstable vitiligo disease. In agreement with previous studies, disease stability (pre- and post-procedure) was correlated with treatment success [10]. Of the 3 patients (25%, 3/12) with retroactively assessed unstable disease, only 1 (33%, 1/3) achieved repigmentation at 12 months.

This novel approach to the MKTP workflow exhibits comparable treatment success rates, when controlling for unstable disease, compared to repigmentation rates of traditional MKTP workflows reported in the literature [9-10]. Our approach successfully reduces the “friction” for dermatology practices to incorporate MKTP into a busy dermatology practice.

237 Yasmeen Ali, MD

Department of Dermatology, Northwestern University Feinberg School of Medicine

| Differences in Microbiome, Diet, and Lifestyle Factors in Vitiligo Patients and Controls

Studies suggest that lifestyle habits including diet, medications, and skincare may impact the microbiome and disease outcomes in vitiligo. One recent study suggested that differences between oral and topical use of antibiotics could alter the gut microbiome and possibly change the course of depigmentation.¹ The purpose of this study is to determine whether nutritional, skin care, and behavioral habits affect the gut and skin microbiota, which may potentially affect vitiligo disease features.

238 Sneha Poondru, BA

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

| Use of Complementary and Alternative Medicine in Vitiligo

Although complementary and alternative medicine (CAM) is used less frequently among those with vitiligo in the United States compared to other countries,^[1] those with skin of color were more likely to utilize CAM and have more positive perceptions of CAM. Since many participants did not discuss their use of CAM with their provider, it is important for providers to routinely ask, especially since some CAM products may interact with other medications and cause adverse side effects. Further investigation on the efficacy of the various supplements and topical agents and their role as adjuvant therapy in vitiligo management is warranted.

239 Sneha Poondru, BA

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

| Use of Camouflage in Vitiligo: A Cross-Sectional Survey of Perceptions of Those With Vitiligo

Since camouflage use may help improve self-esteem and quality of life, especially for those with skin of color, providers should increase patient education on products available for use. There may also be a need for more inclusive color shades for these products as those with skin of color are more likely to report difficulties finding the correct shade.

242 Jihane Belcadi, MD

IBN SINA University Hospital

| COVID 19 Vaccine-Induced Vitiligo: A Series of 24 Cases

The COVID-19 epidemic changed our health programmes and vaccination has become a daily practice. Since the number of reported autoimmune reactions after COVID-19 vaccination is increasing, the occurrence of de novo vitiligo after vaccination is not a mere coincidence and therefore it is reasonable to include it in the list of possible adverse events.

249 Youwen Zhou, MD

University of British Columbia

| Vitiligo Responding to Topical Tapinarof

Tapinarof is a new topical immunomodulating drug for the treatment of psoriasis. Its mechanism of action is not clearly understood, but has been shown to act as an arylhydrocarbon receptor agonist. It also has strong antioxidant effects. The case reported here, if replicated by others, suggests that tapinarof potentially can become a therapy for vitiligo, a disease that involves oxidative stress-induced death of melanocytes.

253 Suresh Joshipura, MBBS, MD

Skin Center

| Quality of Life in Vitiligo : Tip of an Iceberg

This study confirms that the psychological impacts from vitiligo are significant. Vitiligo is probably one of the most common causes of disfigurement, impaired appearance. Apart from causing physical discomfort, they influence the patient's personal and social life, daily functioning and psychologic status. Counselling by dermatologist, public support group and cognitive behaviour therapy is very important to help improve quality of life.

256 Rohan Shah, BA

Rutgers New Jersey Medical School

| Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation

Our case highlights a three-fold concept regarding the use of tofacitinib for vitiligo. First, it reiterates the clinical efficacy of oral tofacitinib for vitiligo. Secondly, it demonstrates a rare, but serious adverse effect associated with tofacitinib that must be accounted for by the clinician at follow up. Finally, it offers a foundation for further exploration in adjusting treatment protocol by decreasing dose of tofacitinib or discontinuing entirely when disease has stabilized.

260 Kevin Patel, MD

University of Texas at Austin Dell Medical School

| The Association of Vitiligo and Inflammatory Arthritis: A National Inpatient Sample in US Adults

The present study found strong associations between vitiligo and multiple autoimmune arthritic conditions including psoriatic arthritis, rheumatoid arthritis, and other inflammatory arthritis. Vitiligo was not associated with reactive arthritis and ankylosing spondylitis. This study expands on previous studies that showed higher rates of inflammatory arthritis in persons with vitiligo compared to those without vitiligo. The results of this study have substantial clinical and public health significance. Vitiligo patients may benefit from increased screening for arthropathy with appropriate referral and management for rheumatologic care. Strengths of this study include the use of a nationally representative sample of all US hospitalizations, with over 90 million records and a large number of vitiligo cases. Limitations of the study include the inability to perform temporal analysis of comorbidities, lack of data on severity of disease, or treatments used prior to and during hospitalization. In conclusion, vitiligo is associated autoimmune arthritis. Further studies are needed to confirm these associations, their underlying mechanisms and ideal strategies for their prevention and treatment of these conditions.

QUICK ACCESS & DOWNLOAD



Watch and Learn

ABSTRACT PRESENTATIONS AND INVITED SPEAKERS



2024 VIS

2024.VITILIGOSYMPOSIUM.ORG



Updated GVF website



GVF Newsletter



Support Groups



Vitiligo Social Network



World Vitiligo Day-USA

JUNE 23-25, 2023



Children's Books

RECOMMENDATIONS



**Check out the 2022 GVF
Annual Report!**



Save the Date!

Cairo, Egypt

December 6-8, 2024

